• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
PLATINUM DRUGS PRESENTATION
 

PLATINUM DRUGS PRESENTATION

on

  • 428 views

 

Statistics

Views

Total Views
428
Views on SlideShare
428
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    PLATINUM DRUGS PRESENTATION PLATINUM DRUGS PRESENTATION Presentation Transcript

    • PLATINUM DRUGSUDESHNA SAHA ~ Chem.3 Yr
    • INTRODUCTIONPlatina del pinto - Pt - 78
    •  Cis Pt (NH3)2 discovered by M.PEYRON, 1845. In 1965, BARNETT ROSERBERG discovered, Electrolysis of Platinum electrode produce CISPLATIN. Cis Pt gets approval for clinical use in 1978.
    • CARBOPLATIN was discoveredin1889 at CANCER RESEARCH CENTRE, London.
    • OXAPLATIN wasdiscovered in 1976 atNagoya City UniversIty byProfessor Yoshinori Kidani.
    • PROGRESS : 1992 Corelation of increased nucleotide – excision repair with lower response Platinum based chemotherapy in patients with Ovarian Cancer was observed, in 1992. It was also in 1992, that the first clinical study showed the promising result of OXAPLATIN when used in combination with 5- fluorouracil in patients with Colorectal Cancer.
    • PROGRESS : 1993 & 97 1993 : It was in 1993, the first patient treated with an orally administered PLATINUM drug, SATRAPLATIN (JM216). 1997 : It was in 1997, the first patient was treated with PICOPLATIN (JM473).
    • PROGRESS : 1999 & 2002 1999 : Molecular defect in nucleotide - excision Repair, was identified that causes hypersensitivity of some testicular Cancer to CISPLATIN. 2002 : OXAPLATIN gets initial approval from US FDA for Colorectal Cancer treatment. 2002 : Identification of the role of COPPER TRANSPORTER CTR1 in transporting CISPLATIN into cells, was also in 2002.
    • PROGRESS : 2006 & 2007 2006 : BEVACIZUMAB got approved for treatment in non-cell lung cancer used in combination with CARBOPLATIN & PACLITAXEL. 2007 : It was in 2007, that SATRAPLATIN was taken into consideration for approval by the US FDA for Prostate Cancer.
    • PROGRESS : 2009 Researchers have now identified a way to enhance the in vitro anticancer effects of the commonly used platinum-based drug Cisplatin and hope that it might be possible to translate these data into the development of a clinical strategy to enhance the anti-cancer effects of platinum-based drugs.
    • PROGRESS : 2009 Researchers in the Department of Chemistry at Wake Forest University in collaboration with colleagues at the Wake Forest University Health Sciences Comprehensive Cancer Center have developed a new class of platinum-based anti- tumor drugs that animal studies have shown to be 10 times more effective than current treatments in destroying certain types of lung cancer cells.
    • PROGRESS 2010 A new light activate Platinum based complex compound known as trans, trans, trans – [ Pt (N3)2 (OH)2 (Py)2 ], was discovered, that can be activated by normal visible Blue or even Green light, which can used as `light activation` to kill Cancer cells in a much more targeted way. It is 80 times more powerful, it is easy to work & stable & it can be flushed out of the body after use as it is water soluble.
    • LIMITATIONS CISPLATIN CARBOPLATIN  MYELOSUPRESSION NEPHROTOXICITY NEURO-TOXICITY OTOTOXICITY
    • NEPHROTOXICITY~ The property ofharming kidney cellsor causing kidneyfailure.
    • NEUROTOXICITYBEFORE AFTER
    • OTOTOXICITY~ Ototoxicity isdrug or chemicaldamage to theinner ear.
    • MYELOSUPPRESSION~ Inhibition of bonemarrow activity, resultingin decreased production ofblood cells and platelets.
    • CISPLATIN RESISTANCE It is a disease in which patients becomes non responsive to Cisplatin.
    • FUTURE ~ BNP 7787Overcomes Cisplatin resistance.Overcomes Cisplatin resistance.
    • SOME OTHER PT DRUGS ~ APROVED FOR MARKETING NEDAPLATIN ------------------- LOBAPLATIN ----------------- HEPTAPLATIN ----------------
    • DRUGS UNDER CLINICAL TRIAL SATRAPLATIN ---------------- PICOPLATIN ------------------ And ot s… her
    • Conclusion…Precious metals are not only precious as wealthbut far more precious for health also.
    • ThankThank You